Hilmi Erdem Gözden, MD, is a graduate of Uludağ University Faculty of Medicine. He completed his residency in Internal Medicine at the University of Health Sciences (SBÜ) Ümraniye Training and Research Hospital and his subspecialty training in Hematology at the Division of Hematology, Uludağ University Faculty of Medicine. He currently works at the Hematology Clinic of SBÜ Bursa Yüksek İhtisas Training and Research Hospital and is pursuing a PhD in Translational Medicine at Bursa Uludağ University.
His main areas of work include chronic myeloid leukemia, PNH, multiple myeloma, acute leukemias, hematopoietic stem cell transplantation, and molecular genetics, as well as artificial intelligence, machine learning, and AI-assisted clinical decision support systems in clinical hematology. He is a member of the Turkish Society of Hematology (THD) and the European Hematology Association (EHA). He served two terms as secretary of the THD Scientific Subcommittee on Hemostasis and Thrombosis and has been an active member of the THD Artificial Intelligence Subcommittee since 2025.
His recent academic work focuses in particular on the integration of artificial intelligence into clinical decision-making, generative and agentic AI, machine learning–based predictive models, and human–AI decision concordance. He published seven articles in peer-reviewed journals in 2025–2026. His study comparing hematologists' decisions in chronic myeloid leukemia with those of an explainable, ELN-based, policy-aware RAG system has been accepted as a poster presentation at the 68th ASH Annual Meeting.
